Thumbs Up/Thumbs Down: The UN fum­bles bad­ly over ac­cess to drugs while de­vel­op­ers think again about R&D strate­gies

9 years ago
Bioregnum
Opinion

No­vo’s big re­veal: GLP-1 drug semaglu­tide cuts car­dio risks, but just may blind you

9 years ago
R&D

An ac­quis­i­tive Cel­gene looks ready to pop a new mul­ti­ple myelo­ma deal

9 years ago
Deals

Am­gen, No­var­tis cel­e­brate promis­ing mi­graine da­ta, but Te­va and Alder are prepar­ing to crash the par­ty

9 years ago
R&D

The gam­ma delta T cell gam­bit in­spires a small Lon­don biotech start­up with big ideas

9 years ago
Startups

No­vavax shares are rout­ed af­ter its big PhI­II RSV vac­cine tri­al flops

9 years ago
R&D

IPO-bound Intar­cia hauls in $215M, and plans to add more; Pelo­ton rais­es $52M round

9 years ago
News Briefing

Ar­alez fi­nal­ly gets an FDA OK for its car­dio drug Yosprala, starts hir­ing sales reps

9 years ago
Pharma

Mer­ck, Pfiz­er tout PhI­II di­a­betes da­ta as er­tugli­fozin heads to the FDA

9 years ago
R&D

Rigel co-founder, R&D staff jet­ti­soned in the long-await­ed lead up to an FDA pitch

9 years ago
R&D

Ei­sai launch­es biotech di­vi­sion in Mass­a­chu­setts aimed at Alzheimer’s, I/O and au­toim­mune dis­eases

9 years ago
R&D

Acel­Rx takes an­oth­er step in its re­cov­ery pro­gram, prep­ping a pain med pitch to the FDA

9 years ago
R&D

Aerie shares rock­et up as glau­co­ma com­bo drug scores pos­i­tive da­ta

9 years ago
R&D

Agios sets out to raise $150M; AC Im­mune IPO sets val­u­a­tion at $700M

9 years ago
R&D
News Briefing

The FDA con­firms that Sarep­ta neme­sis Ronald Farkas has left the agency

9 years ago
Pharma

Roche’s megablock­buster MS can­di­date ocre­lizum­ab posts promis­ing head-to-head da­ta

9 years ago
R&D

At­las part­ner Sa­ha takes the helm at Delinia, look­ing to dis­rupt au­toim­mune R&D

9 years ago
R&D

On a spree, Al­ler­gan forks over a big pre­mi­um to nab Vi­tae’s au­toim­mune drugs for $639M

9 years ago
R&D

So Take­da wants to do up to $20B in M&A? Wel­come to the bid­ding war for US biotechs

9 years ago
Deals

Third Rock ramps up a $57M up­start fo­cus­ing on pro­teins in mo­tion

9 years ago
Financing
Startups

Pro­to­cols: RaNA re­cruits Shire vet as new CSO; Catal­ent buys Phar­matek

9 years ago
News Briefing

Yale’s David Spiegel in­spires an­oth­er im­muno-on­col­o­gy R&D spin­out fo­cused on An­ti­body Re­cruit­ing Mol­e­cules

9 years ago
People
R&D

J&J, GSK ad­vance their PhI­II IL-6 rheuma­toid arthri­tis drug down to a busy red zone

9 years ago
R&D

Cap­tured in a harsh spot­light, biotech uni­corn Mod­er­na names Melis­sa Moore as its new CSO

9 years ago
R&D
First page Previous page 1163116411651166116711681169 Next page Last page
A service from the Financial Times